Australia reports second blood clot case ‘likely’ linked to AstraZeneca Covid vaccine

Health authorities have concluded a second case of a rare blood clot syndrome in Australia “is likely” linked to the アストラゼネカ ワクチン.

The case occurred in a woman in her 40s who received the AstraZeneca Covid-19 jab in Western Australia, the Therapeutic Goods Administration announced on Tuesday. She is receiving treatment in hospital and is in a stable condition.

木曜日に Australia’s vaccine rollout was thrown into disarray by an advisory slapped on the AstraZeneca vaccine warning people under 50 it may cause extremely rare but potentially deadly blood clots.

Health authorities estimate the syndrome affects four to six cases per 1 million AstraZeneca vaccine recipients, but it can cause a death rate of up to 25% when it occurs. 免疫に関するオーストラリア技術諮問グループ, an independent group of medical experts that advises the health minister, 前記: “More cases can be expected to occur, albeit rarely.”

The TGA said its vaccine safety investigation group concluded on Monday that “a recently reported case of thrombosis with thrombocytopenia is likely to be linked to vaccination”.

The case is the second instance in Australia of blood clots believed to be linked to the AstraZeneca vaccine, 後 a 44-year old Melbourne man also developed the syndrome earlier in April.

“There have been about 700,000 doses of AstraZeneca Covid-19 vaccine administered in Australia to date, so while numbers are small, two cases … equates to a frequency of 1 in 350,000,” the TGA said.

“The UK regulator … has concluded from its review of cases reported in the UK that the overall risk of these rare blood clots was approximately 1 に 250,000 who receive the vaccine.”

The TGA said it used an “internationally accepted” method to rate the certainty of a link between the blood clots and the vaccine. It concluded “the case is similar to cases seen in Europe and the United Kingdom of a rare clotting disorder” because it included blood clots in the veins, low blood platelet count and blood test results consistent with other cases.

“Diagnosis was complicated by some ambiguous imaging findings and the need to run additional confirmatory blood tests.”

The TGA said that common side-effects of Covid-19 vaccines include fever, sore muscles, tiredness and headache, and these are “not of concern unless severe or persistent”.

“The reports of these rare clotting complications have occurred later (between day 4 そして 20 after vaccination) and have generally been severe, requiring hospitalisation," と言いました.

The TGA advised people to seek medical attention if a few days after vaccination they experienced:

Earlier on Tuesday, the office of the health minister, Greg Hunt, revealed Australia will not purchase Johnson & Johnson’s Covid-19 vaccine, citing concerns that it is an adenovirus vaccine, of the same type as the AstraZeneca.

There are similar concerns about the Johnson & Johnson vaccine, と Europe’s drug regulator reviewing rare blood clots in four people in the US who received the adenovirus vaccine.

コメントは締め切りました.